子宮内膜癌治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Endometrial Cancer - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0632
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:1393
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Endometrial Cancer – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer – Pipeline Review, H2 2019, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 75, 66, 15, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Endometrial Cancer – Overview
Endometrial Cancer – Therapeutics Development
Endometrial Cancer – Therapeutics Assessment
Endometrial Cancer – Companies Involved in Therapeutics Development
Endometrial Cancer – Drug Profiles
Endometrial Cancer – Dormant Projects
Endometrial Cancer – Discontinued Products
Endometrial Cancer – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Endometrial Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Endometrial Cancer - Pipeline by Aadi Bioscience Inc, H2 2019
Endometrial Cancer - Pipeline by AbbVie Inc, H2 2019
Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2019
Endometrial Cancer - Pipeline by Abpro Corp, H2 2019
Endometrial Cancer - Pipeline by Acepodia Biotech Inc, H2 2019
Endometrial Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Endometrial Cancer - Pipeline by Aduro BioTech Inc, H2 2019
Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
Endometrial Cancer - Pipeline by Almac Discovery Ltd, H2 2019
Endometrial Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Endometrial Cancer - Pipeline by Apexigen Inc, H2 2019
Endometrial Cancer - Pipeline by Apollomics Inc, H2 2019
Endometrial Cancer - Pipeline by Arcus Biosciences Inc, H2 2019
Endometrial Cancer - Pipeline by ArQule Inc, H2 2019
Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Endometrial Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2019
Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2019
Endometrial Cancer - Pipeline by Bantam Pharmaceutical LLC, H2 2019
Endometrial Cancer - Pipeline by Bayer AG, H2 2019
Endometrial Cancer - Pipeline by BeiGene Ltd, H2 2019
Endometrial Cancer - Pipeline by Beijing Neoantigen Biotechnology Co Ltd, H2 2019
Endometrial Cancer - Pipeline by Bicycle Therapeutics Plc, H2 2019

【掲載企業】

Aadi Bioscience Inc
AbbVie Inc
Ability Pharmaceuticals SL
Abpro Corp
Acepodia Biotech Inc
Adlai Nortye Biopharma Co Ltd
Aduro BioTech Inc
Advenchen Laboratories LLC
Almac Discovery Ltd
Apexian Pharmaceuticals Inc
Apexigen Inc
Apollomics Inc
Arcus Biosciences Inc
ArQule Inc
Arrien Pharmaceuticals LLC
Ascenta Therapeutics Inc
AstraZeneca Plc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
BioMed Valley Discoveries Inc
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Celon Pharma SA
Celsion Corp
Checkpoint Therapeutics Inc
Clovis Oncology Inc
Compugen Ltd
Context Therapeutics LLC
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Eisai Co Ltd
Eli Lilly and Co
Epizyme Inc
Esperance Pharmaceuticals Inc
Esperas Pharma Inc
EstryX Pharma Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Fujifilm Holdings Corp
GamaMabs Pharma SA
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
Horizon Therapeutics PLC
Hutchison MediPharma Ltd
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Komipharm International Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Merus NV
Millennium Pharmaceuticals Inc
Moderna Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Morphotek Inc
NeoTX Therapeutics Ltd
NextCure Inc
Northlake International LLC
Novartis AG
NovaTarg Therapeutics Inc
NuCana Plc
Oncoceutics Inc
Oncology Venture U.S. Inc
OncoMed Pharmaceuticals Inc
OncoResponse Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Pfizer Inc
Pharma Mar SA
Pivot Pharmaceuticals Inc
PRISM Pharma Co Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Samumed LLC
Sanofi
SELLAS Life Sciences Group Inc
Shanghai Junshi Bioscience Co Ltd
Splash Pharmaceuticals Inc
Spring Bank Pharmaceuticals Inc
SpringWorks Therapeutics Inc
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Unum Therapeutics Inc
Veru Inc
Vyriad Inc
Xencor Inc
Zymeworks Inc


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[子宮内膜癌治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆